Point72 Asset Management's 5.2% Stake in Design Therapeutics

Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen have jointly filed a Schedule 13G with the SEC, disclosing a 5.2% ownership stake in Design Therapeutics, Inc. The filing indicates that Point72 Asset Management holds investment and voting power over the shares through Point72 Associates, LLC, an investment fund it manages. Point72 Capital Advisors, Inc. is the general partner of Point72 Asset Management, and Steven A. Cohen controls both entities. The shares are held for investment purposes and not for influencing the control of Design Therapeutics. The filing is made pursuant to Rule 13d-1(c) of the Securities Exchange Act of 1934.